Real-world outcomes of PD-L1 inhibitors combined with thoracic radiotherapy in the first-line treatment of extensive stage small cell lung cancer

Real-world outcomes of PD-L1 inhibitors combined with thoracic radiotherapy in the first-line treatment of extensive stage small cell lung cancer

Abstract Background The CREST study showed that the addition of thoracic radiotherapy (TRT) could improve the survival rate in patients with extensive stage small cell lung cancer (ES-SCLC), but whether TRT can bring survival benefit in the era of immunotherapy remains controversial. This study aime...

Full description

Bibliographic Details
Main Authors: Jianfeng Peng, Lemeng Zhang, Liping Wang, Hui Feng, Dongmei Yao, Rui Meng, Xiaomei Liu, Xiaohua Li, Ningbo Liu, Bingxu Tan, Zhaoqin Huang, Shanshan Li, Xiangjiao Meng
Format: Article
Language:English
Published: BMC 2023-07-01
Series:Radiation Oncology
Subjects:
Extensive stage small cell lung cancer
PD-L1 inhibitors
Thoracic radiotherapy
Survival
Toxicity
Online Access:https://doi.org/10.1186/s13014-023-02308-2

Internet

https://doi.org/10.1186/s13014-023-02308-2

Similar Items